222 related articles for article (PubMed ID: 10676886)
1. Involvement of CD28/CTLA4-B7 costimulatory pathway in the development of lymphadenopathy and splenomegaly in MRL/lpr mice.
Takiguchi M; Murakami M; Nakagawa I; Rashid MM; Tosa N; Chikuma S; Hashimoto A; Uede T
J Vet Med Sci; 2000 Jan; 62(1):29-36. PubMed ID: 10676886
[TBL] [Abstract][Full Text] [Related]
2. Blockade of CD28/CTLA4-B7 pathway prevented autoantibody-related diseases but not lung disease in MRL/lpr mice.
Takiguchi M; Murakami M; Nakagawa I; Yamada A; Chikuma S; Kawaguchi Y; Hashimoto A; Uede T
Lab Invest; 1999 Mar; 79(3):317-26. PubMed ID: 10092068
[TBL] [Abstract][Full Text] [Related]
3. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
Zhou T; Weaver C; Linsley PS; Mountz JD
Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
[TBL] [Abstract][Full Text] [Related]
4. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
Lin H; Rathmell JC; Gray GS; Thompson CB; Leiden JM; Alegre ML
J Exp Med; 1998 Jul; 188(1):199-204. PubMed ID: 9653096
[TBL] [Abstract][Full Text] [Related]
6. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis.
Shao H; Woon MD; Nakamura S; Sohn JH; Morton PA; Bora NS; Kaplan HJ
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2016-21. PubMed ID: 11481266
[TBL] [Abstract][Full Text] [Related]
7. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease.
Karandikar NJ; Vanderlugt CL; Bluestone JA; Miller SD
J Neuroimmunol; 1998 Aug; 89(1-2):10-8. PubMed ID: 9726820
[TBL] [Abstract][Full Text] [Related]
8. CD28-specific antibody prevents graft-versus-host disease in mice.
Yu XZ; Bidwell SJ; Martin PJ; Anasetti C
J Immunol; 2000 May; 164(9):4564-8. PubMed ID: 10779758
[TBL] [Abstract][Full Text] [Related]
9. Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice.
Tada Y; Nagasawa K; Ho A; Morito F; Koarada S; Ushiyama O; Suzuki N; Ohta A; Mak TW
J Immunol; 1999 Sep; 163(6):3153-9. PubMed ID: 10477582
[TBL] [Abstract][Full Text] [Related]
10. CD28/B7 costimulation: a review.
Greenfield EA; Nguyen KA; Kuchroo VK
Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
[TBL] [Abstract][Full Text] [Related]
11. Ectopic expression of B7-1 (CD80) on T lymphocytes in autoimmune lpr and gld mice.
Weintraub JP; Cohen PL
Clin Immunol; 1999 Jun; 91(3):302-9. PubMed ID: 10370375
[TBL] [Abstract][Full Text] [Related]
12. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis.
Reynolds J; Tam FW; Chandraker A; Smith J; Karkar AM; Cross J; Peach R; Sayegh MH; Pusey CD
J Clin Invest; 2000 Mar; 105(5):643-51. PubMed ID: 10712436
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses.
Haspot F; Villemain F; Laflamme G; Coulon F; Olive D; Tiollier J; Soulillou JP; Vanhove B
Blood; 2002 Mar; 99(6):2228-34. PubMed ID: 11877302
[TBL] [Abstract][Full Text] [Related]
14. CTLA4-Ig: a novel immunosuppressive agent.
Najafian N; Sayegh MH
Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
[TBL] [Abstract][Full Text] [Related]
15. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection.
Dong VM; Yuan X; Coito AJ; Waaga AM; Sayegh MH; Chandraker A
Transplantation; 2002 Apr; 73(8):1310-7. PubMed ID: 11981427
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
[TBL] [Abstract][Full Text] [Related]
18. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
Fallarino F; Fields PE; Gajewski TF
J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
[TBL] [Abstract][Full Text] [Related]
19. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4.
Mandelbrot DA; Oosterwegel MA; Shimizu K; Yamada A; Freeman GJ; Mitchell RN; Sayegh MH; Sharpe AH
J Clin Invest; 2001 Apr; 107(7):881-7. PubMed ID: 11285307
[TBL] [Abstract][Full Text] [Related]
20. Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells.
Belani R; Weiner GJ
Immunology; 1996 Feb; 87(2):271-4. PubMed ID: 8698390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
